{"id":470601,"date":"2010-03-25T09:17:21","date_gmt":"2010-03-25T13:17:21","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=70275"},"modified":"2010-03-25T09:17:21","modified_gmt":"2010-03-25T13:17:21","slug":"dyax-raises-51-8m-in-stock-deal","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/470601","title":{"rendered":"Dyax Raises $51.8M in Stock Deal"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/finances\/\">Finances<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Dyax (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=DYAX\">DYAX<\/a>), the Cambridge, MA-based maker of a drug for a rare inflammatory disease, <a href=\"http:\/\/investor.dyax.com\/phoenix.zhtml?c=122200&amp;p=irol-newsArticle&amp;ID=1406052&amp;highlight=\">said today<\/a> it has raised $51.8 million in a stock offering. The company sold 17 million shares at $3.25 apiece in a deal underwritten by Jefferies &amp; Company and Needham &amp; Company. Dyax plans to use the money on the commercial push for ecallantide (Kalbitor), a drug for acute attacks of hereditary angioedema.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/03\/25\/dyax-raises-51-8m-in-stock-deal\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Dyax%20Raises%20$51.8M%20in%20Stock%20Deal%20http:\/\/xconomy.com\/?p=70275\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/03\/25\/dyax-raises-51-8m-in-stock-deal\/&#038;t=Dyax%20Raises%20$51.8M%20in%20Stock%20Deal\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/03\/25\/dyax-raises-51-8m-in-stock-deal\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Dyax+Raises+%2451.8M+in+Stock+Deal&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F03%2F25%2Fdyax-raises-51-8m-in-stock-deal%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=b260a3480526243442e998beb9690917&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=b260a3480526243442e998beb9690917&#038;p=1\"\/><\/a><br \/>\n<!-- foo --><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/gw-dwsJQ61I2N52bqM_k12bJYmw\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/gw-dwsJQ61I2N52bqM_k12bJYmw\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/gw-dwsJQ61I2N52bqM_k12bJYmw\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/gw-dwsJQ61I2N52bqM_k12bJYmw\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/AcO8YbxQuEo\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, deals, Finances Luke Timmerman wrote: Dyax (NASDAQ: DYAX), the Cambridge, MA-based maker of a drug for a rare inflammatory disease, said today it has raised $51.8 million in a stock offering. The company sold 17 million shares at $3.25 apiece in a deal underwritten by Jefferies &amp; Company and Needham &amp; Company. Dyax plans [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-470601","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/470601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=470601"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/470601\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=470601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=470601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=470601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}